| abstract |
The invention relates to at least one chemical entity chosen from compounds of formula (I): wherein: R1 represents a group selected from (II): each ring of which optionally contains a further heteroatom N, Z represents an optional substituent halogen, alk represents alkylene or alkenylene, T represents S, O or NH; R2 represents hydrogen, -C1-6alkyl, - C1-3alkyl CONRaRb, - C1-3alkyl CO2 C1-4alkyl, -CO2 C1-4alkyl or - C1-3alkyl CO2H; Ra and Rb independently represent hydrogen, - C1-6alkyl, or together with the N atom to which they are bonded form a 5-, 6- or 7- membered non-aromatic heterocyclic ring optionally containing an additional heteroatom selected from O, N and S, optionally substituted by C1-4alkyl, and optionally the S heteroatom is substituted by O, i.e. represents S(O)n; n represents 0-2; X represents an optional substituent on the indane ring selected from: halogen, - C1-4alkyl, -C2-4alkenyl and -CF3; Y represents a group -(CH2)mNRcRd substituted on the non-aromatic portion of the indane ring; Rc and Rd independently represent hydrogen, - C1-6alkyl, - C1-4alkylOH, or together with the N atom to which they are bonded form a 4-, 5-, 6- or 7- membered non-aromatic heterocyclic ring, the 5-, 6- or 7- membered non-aromatic heterocyclic ring optionally containing an additional heteroatom selected from O, N or S, and the 4-, 5-, 6- or 7- membered non-aromatic heterocyclic ring optionally substituted by C1-4alkyl or halogen; m represents 0-2; and pharmaceutically acceptable derivative(s) thereof. The invention also relates to processes for the preparation of compound(s) of formula (I), pharmaceutical compositions containing compound(s) of formula (I) and to the use of compound(s) of formula (I) in medicine, particularly in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated. |